2009
DOI: 10.1016/j.lungcan.2008.10.013
|View full text |Cite
|
Sign up to set email alerts
|

Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2010
2010
2015
2015

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(13 citation statements)
references
References 12 publications
0
13
0
Order By: Relevance
“…Other alternative treatment modalities have also been attempted. The novel targeted drug imatinib mesylate seems to exert some activity on SFT expressing the wild-type platelet-derived growth factor receptor-b: its in vitro [17] and in vivo [18] inhibitory activity in chemoand radioresistant malignant SFT has recently been demonstrated [11]. Consensus has not been achieved yet concerning radiotherapy and chemotherapy against SFT, but our present report is one supportive of the effectiveness of preoperative radiotherapy for the safe gross total removal of a large pelvic malignant SFT.…”
Section: Case Reportmentioning
confidence: 51%
“…Other alternative treatment modalities have also been attempted. The novel targeted drug imatinib mesylate seems to exert some activity on SFT expressing the wild-type platelet-derived growth factor receptor-b: its in vitro [17] and in vivo [18] inhibitory activity in chemoand radioresistant malignant SFT has recently been demonstrated [11]. Consensus has not been achieved yet concerning radiotherapy and chemotherapy against SFT, but our present report is one supportive of the effectiveness of preoperative radiotherapy for the safe gross total removal of a large pelvic malignant SFT.…”
Section: Case Reportmentioning
confidence: 51%
“…Radiation therapy is of some benefit, when applicable, given in combination with chemotherapy (13). The novel targeted drug imatinib mesilate, which exerts some activity on SFTs expressing the wild-type PDGFR-β, has recently been reported (14,15).…”
Section: Discussionmentioning
confidence: 99%
“…Chemotherapy alone or combined with radiotherapy is reserved for multi-metastatic disease or for ones that cannot be surgically removed. A new therapeutic possibility with imatinib mesylate has recently been reported for metastatic intrapleural SFT characterized by wild type PDGFR-β expression 14,15…”
Section: Discussionmentioning
confidence: 99%